Abstract
Novel effective therapy is limited in head and neck squamous cell carcinoma (HNSCC). Next generation sequencing (NGS) with sophisticated bioinformatics allows the distinct identification of tumour-specific DNA mutations in circulating tumor DNA (ctDNA). CtDNA may represent the real-time genomic profile and biology of cancers to be treated. Identification of molecular characterization of ctDNA may potentially provide a way to precisely treat the patients with novel options.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
